VolitionRx Limited (VNRX) Soars 15% on Positive Coverage From EF Hutton

VolitionRx Limited (VNRX), an epigenetics company, soared 15% plus another 5% in after-hours today. The gains largely come from EF Hutton initiating coverage on VNRX with a buy rating and a price target of $6. Currently, VolitionRx is sitting at under $3, giving VNRX plenty of room to grow.

VolitionRx is also approaching their 52-week high of $3.40 and was featured as a “Top Penny Stock to Buy” on PennyStocks.com

VNRX is a member of the PRISM MedDiagnostics Index, which fell 1.9% for the day.

About Volition

Volition is a multi-national epigenetics company that applies its Nucleosomics™ platform through its subsidiaries to develop simple, easy to use, cost effective blood tests to help diagnose and monitor a range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also to improve their quality of life. The tests are based on the science of Nucleosomics™, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid – an indication that disease is present.

Volition’s research and development activities are centered in Belgium, with an innovation laboratory and office in the U.S. and additional offices in London and Singapore.

 

Share This Article

 

About the Author

VolitionRx Limited (VNRX) Soars 15% on Positive Coverage From EF Hutton

Prism MarketView